Correction: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review

Correction: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review

Saved in:

Bibliographic Details
Main Authors:	Mark T. Reding, Shadan Lalezari, Gili Kenet, Giovanni Di Minno, Jonathan Ducore, Alexander Solms, Anita Shah, Pål André Holme, Lone H. Poulsen, Karina Meijer, Mindy Simpson, Maria Elisa Mancuso
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2024-12-01
Series:	Drugs in R&D
Online Access:	https://doi.org/10.1007/s40268-024-00494-2
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review
by: Mark T. Reding, et al.
Published: (2024-08-01)

Tailored therapy with turoctocog alfa pegol according to patient’s lifestyle and hemorrhagic phenotype: from clinical trial to real-life
by: Ilaria Nichele, et al.
Published: (2024-04-01)

Acquired Hemophilia A successfully treated with rituximab
by: Giovanni D'Arena, et al.
Published: (2015-02-01)

Certolizumab pegol in therapy for rheumatoid arthritis
by: Galina Viktorovna Lukina, et al.
Published: (2012-06-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS
by: Sh. F. Erdes
Published: (2016-02-01)

EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS
by: T. V. Korotaeva, et al.
Published: (2015-10-01)

Intracranial hemorrhage before start of prophylaxis in children with hemophilia: incidence, timing, and potential for prevention
by: Nadine G. Andersson, et al.
Published: (2024-11-01)

Experience with long-term use of certolizumab pegol (Cimzia)
by: Karine Arnoldovna Lytkina, et al.
Published: (2013-10-01)

Organizing pneumonia in a patient following treatment of chronic hepatitis B with pegylated interferon alfa-2b: A case report
by: Bing Tian, et al.
Published: (2025-01-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF TAKAYASU ARTERITIS: THE FIRST EXPERIENCE AND PROSPECTS
by: P. I. Novikov, et al.
Published: (2018-07-01)

QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL
by: Vera Nikolayevna Amirdjanova, et al.
Published: (2012-10-01)

Design of an international, phase IV, open-label study of simoctocog alfa in women/girls with hemophilia A undergoing surgery (NuDIMENSION)
by: Natascha Marquardt, et al.
Published: (2024-11-01)

Management of common autoimmune diseases in patients with myeloproliferative neoplasms treated with pegylated interferon alfa—case report, review of the literature and multidisciplinary clinical practice recommendations
by: Axel Rüfer, et al.
Published: (2025-05-01)

New aspects of the pharmacotherapy of rheumatoid arthritis: a focus on certolizumab pegol
by: Evgeniy L'vovich Nasonov, et al.
Published: (2011-02-01)

Certolizumab pegol in severe hidradenitis suppurativa in pregnancy: A case report
by: Paolo Gisondi, et al.
Published: (2025-01-01)

New opportunities in Haemophilia treatment: Efmoroctocog Alfa for patients with Haemophilia A
by: Giovanna Elisa Calabrò, et al.
Published: (2022-01-01)

First-in-human pharmacokinetic, safety, and preliminary efficacy of single- and multiple-dose FRSW117, a novel PEGylated recombinant factor VIII-Fc fusion protein with an extended half-life, in patients with severe hemophilia A
by: Feng Xue, et al.
Published: (2025-06-01)

New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol
by: Dmitry Evgenyevich Karateev, et al.
Published: (2012-04-01)

A real-world pharmacovigilance study of Certolizumab pegol based on FAERS database
by: Meng Liu, et al.
Published: (2025-08-01)

Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor
by: Nicholas B. Abt, et al.
Published: (2014-01-01)

Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective
by: Alberto A Gabizon, et al.
Published: (2025-01-01)

Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis
by: Filip van den Bosch, et al.
Published: (2024-08-01)

Outcomes and management of invasive procedures in participants with hemophilia A post gene therapy: a post hoc analysis of the GENEr8-1 phase III trial
by: Doris V. Quon, et al.
Published: (2024-12-01)

EFFICACY AND SAFETY OF THE COMBINATION OF RIBAVIRIN AND PEGYLATED INTERFERON ALFA-2A IN PATIENTS WITH CHRONIC HEPATITIS C: THE RESULTS OF TWO MULTICENTER, PROSPECTIVE, OPEN, NON-COMPARATIVE CLINICAL TRIALS
by: K. V. Zhdanov, et al.
Published: (2018-01-01)

Development and Characterization of PEGylated Chromatographic Monoliths as a Novel Platform for the Separation of PEGylated RNase a Isomers
by: Calef Sánchez-Trasviña, et al.
Published: (2019-01-01)

Factor VIII prophylactic therapy reduces neurological complications in patients with Hemophilia A
by: José Marcelino Aragão FERNANDES, et al.

Analysis of phytosterols encapsulated in pegylated liposomes
by: Joanna Igielska-Kalwat, et al.
Published: (2025-08-01)

Study of the immunotoxic properties of pegylated hyaluronidase
by: K. I. Ershov, et al.
Published: (2023-10-01)

Pegylation, as method of production prolonged forms of biopharmaceutical drugs (pegylated granulocyte colony-stimulating factor as case of study)
by: I. А. Puchkov, et al.
Published: (2014-04-01)

MYOCARDIAL INFARCTION AND HEMOPHILIA
by: A. S. Galyavich, et al.
Published: (2016-03-01)

MANAGEMENT OF INHIBITORS IN HEMOPHILIA
by: Gaye Kalacı Katayıfçı
Published: (2024-12-01)

HEMOPHILIA: ADVANCES IN TREATMENTS
by: Nurgül Karakaya
Published: (2024-12-01)

Risankizumab and Certolizumab Pegol Dual-Targeted Therapy for Crohn’s Disease and Axial Spondyloarthritis: A Case Report
by: Anouk Lehmann, et al.
Published: (2024-12-01)

LONG-TERM RETENTION RATE OF CERTOLIZUMAB PEGOL IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: DATA FROM THE TURKBIO REGISTRY
by: Ahmet Karataş, et al.
Published: (2025-06-01)

Single-chain recombinant clotting factor VIII (lonoctocog alfa): clinical experience in Russia
by: M. V. Kosinova
Published: (2022-02-01)

Joint health status in people with moderate hemophilia A: a cross-sectional multicenter study
by: Ilenia Lorenza Calcaterra, et al.
Published: (2025-02-01)

Neutrophils-mediated accelerated blood clearance phenomenon in beagles and rats based on the cross-injection of non-PEGylated and PEGylated nanoemulsions
by: Mengyang Liu, et al.
Published: (2025-06-01)

One-Year Outcomes in Subjects Developing Macular Neovascularization While Undergoing Avacincaptad Pegol Therapy for Geographic Atrophy
by: Rush RB, et al.
Published: (2025-01-01)

Real-World Outcomes with Complement Inhibitors for Geographic Atrophy: A Comparative Study of Pegacetacoplan versus Avacincaptad Pegol
by: Rush RB, et al.
Published: (2025-03-01)

Estado vegetativo-alfa persistente
by: R. Oliveira-Souza, et al.
Published: (1989-06-01)